Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brigham and Women's Hospital

http://www.brighamandwomens.org

Latest From Brigham and Women's Hospital

Amgen Doubles Down On AI, Genomic Investments In R&D

David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.

Artificial Intelligence Strategy

Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D

Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.

Leadership Companies

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies

Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

Financing Deals
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register